JAFFER A. AJANI, M.D.
Osteopathic Medicine at Holcombe Blvd, Houston, TX

5189025, Feb 23, 1993

May 14, 1990

7/510028

Jaffer Ajani - Houston TX
Bruce Grossie - Houston TX
Kenji Nishioka - Houston TX
David M. Ota - Houston TX

Board of Regenets, The University of Texas System - Austin TX

A61K 3170, A61K 31415, A61K 3140, A61K 31195

514 23

Disclosed are total parenteral nutrition formulations which include essential amino acids in combination with either arginine or ornithine, for use in the detection of recurrent malignant disease in patients. Such formulations stimulate tumor-specfic polyamine production to a greater extent than non-tumor related polyamine production. Additionally, such formulations were found to specifically promote an increase in red blood cell putrescine levels of tumor-bearing rats. Nontumor-bearing rats were not found to be similarly reactive to these formulations. Methods for making and administering these formulations as well as their use in preventing DFMO-induced toxicity are also disclosed. Also disclosed are parenteral nutritional formulations which include both citrulline and ornithine which have an arginine concentration of less than about 0. 10% by weight final concentration.

4988724, Jan 29, 1991

Dec 9, 1988

7/282126

Jaffer Ajani - Houston TX
Bruce Grossie - Houston TX
Kenji Nishioka - Houston TX
David M. Ota - Houston TX

Board of Regents, The University of Texas System - Austin TX

A61K 3141, A61K 3140, A61K 31195

514399

Disclosed are total parenteral nutrition formulations which include essential amino acids in combination with either arginine or ornithine, for use in the detection of recurrent malignant disease in patients. Such formulations stimulate tumor-specific polyamine production to a greater extent than non-tumor related polyamine production. Additionally, such formulations were found to specifically promote an increase in red blood cell putrescine levels of tumor-bearing rats. Nontumor-bearing rats were not found to be similarly reactive to these formulations. Methods for making and administering these formulations as well as their use in preventing DFMO-induced toxicity are also disclosed. Also disclosed are parenteral nutritional formulations which include both citrulline and ornithine which have an arginine concentration of less than about 0. 10% by weight final concentration.

5162373, Nov 10, 1992

Aug 28, 1989

7/399778

Jaffer Ajani - Houston TX
Bruce Grossie - Houston TX
Kenji Nishioka - Houston TX
David M. Ota - Houston TX

Board of Regents, The University of Texas System - Austin TX

A01N 3744

514564

Disclosed are total parenteral nutrition formulations which include essential amino acids in combination with either arginine or ornithine, for use in detection of recurrent malignant disease in patients. Such formulations stimulate tumor-specific polyamine production to a greater extent than non-tumor related polyamine production. Additionally, such formulations were found to specifically promote an increase in red block cell putrescine levels of tumor-bearing rats. Nontumor-bearing rats were not found to be similarly reactive to these formulations. Methods for making and administering these formulations as well as their use in preventing DFMO-induced toxicity are also disclosed. The present invention also comprises formulations for use in the rejuvinati o BACKGROUND OF THE INVENTION The government may own certain rights in the present invention pursuant to NCI grant RDI CA3 4-465 and NCI grant ROI CA3 4-465.

2010021, Aug 26, 2010

Dec 10, 2007

12/518441

Rajyalakshmi Luthra - Missouri City TX, US
Jaffer A. Ajani - Houston TX, US
Maden G. Luthra - Missouri City TX, US

C12Q 1/00, C07H 21/02

435 6, 536 2433, 536 231

The present invention generally regards gene expression profiling of esophageal cancers, including localized esophageal cancers. In particular, gene expression for a particular group of genes identifies individuals that are either going to be responsive to cancer therapy, for example chemotherapy and/or radiation, or that are not going to be responsive to cancer therapy. Exemplary genes having such expression profiles include, for example, PERP, S100A2, and SPRR3.

4859452, Aug 22, 1989

Jan 13, 1987

7/002890

Jaffer Ajani - Houston TX
Bruce Grossie - Houston TX
Kenji Nishioka - Houston TX
David M. Ota - Houston TX

Board of Regents, The University of Texas System - Austin TX

A61K 0000

424 10

Disclosed are total parenteral nutrition formulations which include essential amino acids in combination with either arginine or ornithine, for use in the detection of recurrent malignant disease in patients. Such formulations stimulate tumor-specific polyamine production to a greater extent than non-tumor related polyamine production. Additionally, such formulations were found to specifically promote an increase in red blood cell putrescine levels of tumor-bearing rats. Nontumor-bearing rats were not found to be similarly reactive to these formulations. Methods for making and administering these formulations as well as their use in preventing DFMO-induced toxicity are also disclosed.